Deep Bio

Deep Bio Inc. is a South Korean company focused on AI-driven healthcare and biotechnology, particularly in digital pathology and cancer diagnostics. Founded in October 2015 by Kim Sun-Woo, the company is headquartered in Seoul and employs between 11 to 50 people. Deep Bio has raised approximately $8.4 million in funding, including a notable $5 million Series A round and a Series B investment in March 2020. It is recognized as the first company in South Korea to receive approval for an AI-based cancer diagnostic support solution from the Ministry of Food and Drug Safety.

The company offers advanced AI-powered diagnostic solutions, including the DeepDx® suite, which analyzes biopsy images to detect and grade various cancers. Deep Bio collaborates with leading medical institutions in South Korea and the United States to enhance cancer research and diagnostics. Its technology utilizes deep learning algorithms to improve diagnostic accuracy and efficiency, aiming to transform oncology by providing pathologists and clinicians with tools that support faster and more informed treatment decisions.